Difference between revisions of "Team:Kent/HP/Silver"
| (9 intermediate revisions by the same user not shown) | |||
| Line 188: | Line 188: | ||
margin: auto; | margin: auto; | ||
margin-bottom:200px; | margin-bottom:200px; | ||
| − | margin-top: | + | margin-top:0px; |
width: 1200px; | width: 1200px; | ||
opacity:0.85; | opacity:0.85; | ||
| Line 348: | Line 348: | ||
#textbox2{ | #textbox2{ | ||
display:inline-block; | display:inline-block; | ||
| − | margin: | + | margin: 0px 0 0px 0; |
width:1000px; | width:1000px; | ||
border-radius:20px; | border-radius:20px; | ||
| Line 359: | Line 359: | ||
} | } | ||
| + | } | ||
| + | .connector{ | ||
| + | text-align:center; | ||
| + | } | ||
| + | .connector img{ | ||
| + | display:inline-block; | ||
| + | width:50px; | ||
| + | } | ||
#box1 p{ | #box1 p{ | ||
| Line 373: | Line 381: | ||
} | } | ||
| − | + | #title2{ | |
| + | padding: 50px 0 50px 0; | ||
| + | } | ||
.centerizer{ | .centerizer{ | ||
width:100%; | width:100%; | ||
text-align:center; | text-align:center; | ||
| − | margin: | + | margin: 0 0 0 0; |
} | } | ||
.centerizer span{ | .centerizer span{ | ||
| Line 532: | Line 542: | ||
<img src = "https://static.igem.org/mediawiki/2017/thumb/1/12/T--Kent--SilverHeader2.png/766px-T--Kent--SilverHeader2.png" id="header2"> | <img src = "https://static.igem.org/mediawiki/2017/thumb/1/12/T--Kent--SilverHeader2.png/766px-T--Kent--SilverHeader2.png" id="header2"> | ||
</div> | </div> | ||
| − | + | ||
| − | + | ||
| − | + | ||
| − | + | ||
<div id="box1"> | <div id="box1"> | ||
| − | |||
| − | |||
| − | |||
| − | |||
| − | |||
| Line 552: | Line 554: | ||
</div> | </div> | ||
| − | <div class="centerizer"> | + | <div class="centerizer" id="title2"> |
<span>Why CRISPR-dCas13a (C2C2)?</span> | <span>Why CRISPR-dCas13a (C2C2)?</span> | ||
<div class="SlineSeparator"></div> | <div class="SlineSeparator"></div> | ||
</div> | </div> | ||
| + | |||
<div id="box2"> | <div id="box2"> | ||
| Line 561: | Line 564: | ||
<p>We were introduced to CRISPR-Cas9 as a tool for targeting cellular mRNA translation through Dr. Peter Ellis, a lecturer in Molecular Biology and Reproduction. However, through research, we discovered that Cas9 is a DNA endonuclease, meaning it recognizes DNA targets and cuts them. It would need to be ‘tricked’ by molecular means. C2C2, however, or Cas13a is an RNA endonuclease, meaning it cuts the RNA rather than the DNA. There are two key differences when comparing Cas13 to CAS9: Firstly, Cas13 recognizes RNA rather than DNA. Secondly, once the target is recognized, it acts promiscuously and starts to ‘chew up’ all of the RNA around it, not only the intended target sequence. <br><img src="https://static.igem.org/mediawiki/2017/3/3c/T--Kent--LogbookP5.png"><img src="https://static.igem.org/mediawiki/2017/5/52/T--Kent--LogbookP3.png"> | <p>We were introduced to CRISPR-Cas9 as a tool for targeting cellular mRNA translation through Dr. Peter Ellis, a lecturer in Molecular Biology and Reproduction. However, through research, we discovered that Cas9 is a DNA endonuclease, meaning it recognizes DNA targets and cuts them. It would need to be ‘tricked’ by molecular means. C2C2, however, or Cas13a is an RNA endonuclease, meaning it cuts the RNA rather than the DNA. There are two key differences when comparing Cas13 to CAS9: Firstly, Cas13 recognizes RNA rather than DNA. Secondly, once the target is recognized, it acts promiscuously and starts to ‘chew up’ all of the RNA around it, not only the intended target sequence. <br><img src="https://static.igem.org/mediawiki/2017/3/3c/T--Kent--LogbookP5.png"><img src="https://static.igem.org/mediawiki/2017/5/52/T--Kent--LogbookP3.png"> | ||
</p> | </p> | ||
| + | </div> | ||
| + | <div class="centerizer"> | ||
| + | <div class="connector"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/thumb/f/f4/T--Kent--HP9.png/133px-T--Kent--HP9.png"> | ||
</div> | </div> | ||
<div id="textbox2" > | <div id="textbox2" > | ||
| Line 567: | Line 574: | ||
</p> | </p> | ||
</div> | </div> | ||
| + | </div> | ||
| + | <div class="centerizer"> | ||
| + | <div class="connector"> | ||
| + | <img src="https://static.igem.org/mediawiki/2017/thumb/f/f4/T--Kent--HP9.png/133px-T--Kent--HP9.png"> | ||
</div> | </div> | ||
</div> | </div> | ||
| Line 594: | Line 605: | ||
<label class="hull-title" for="cb2">Professor Michelle Garrett</label> | <label class="hull-title" for="cb2">Professor Michelle Garrett</label> | ||
<label class="hull-close" for="acc-close"></label> | <label class="hull-close" for="acc-close"></label> | ||
| − | <div class="hull-content">When conceptualizing our project, we realized we would need to transfect our cell lines into mammalian cells if we wanted to have any use of it as a potential diagnostic tool, as it would be relatively useless in its bacterial cell host. Professor Garrett was able to guide us in the direction of the Smales Group at our University, providing us with the resources needed to make the transfections possible.</div> | + | <div class="hull-content">When conceptualizing our project, we realized we would need to transfect our cell lines into mammalian cells if we wanted to have any use of it as a potential diagnostic tool, as it would be relatively useless in its bacterial cell host. Professor Garrett was able to guide us in the direction of the Smales Group at our University, providing us with the resources needed to make the transfections possible.<br><img src="https://static.igem.org/mediawiki/2017/2/2b/T--Kent--HP8.png"></div> |
</section> | </section> | ||
<input type="radio" name="droptext" id="acc-close" /> | <input type="radio" name="droptext" id="acc-close" /> | ||
| Line 601: | Line 612: | ||
<label class="hull-title" for="cb3">Ian Brown, Microscopy Suite Facility Manager</label> | <label class="hull-title" for="cb3">Ian Brown, Microscopy Suite Facility Manager</label> | ||
<label class="hull-close" for="acc-close"></label> | <label class="hull-close" for="acc-close"></label> | ||
| − | <div class="hull-content">As CRISPR itself has only recently been discovered as an mRNA tracking tool, most of the project entailed repeated trial and error. We realized before we even thought of imaging, we needed to ensure we had the appropriate controls for comparative and evaluative reasons. We were able to generate a repeatable layout for future imaging purposes that Ian Brown was able to confirm would be adequate in imaging our cells accurately | + | <div class="hull-content">As CRISPR itself has only recently been discovered as an mRNA tracking tool, most of the project entailed repeated trial and error. We realized before we even thought of imaging, we needed to ensure we had the appropriate controls for comparative and evaluative reasons. We were able to generate a repeatable layout for future imaging purposes that Ian Brown was able to confirm would be adequate in imaging our cells accurately<br> |
<img src="https://static.igem.org/mediawiki/2017/9/9d/T--Kent--HP5.png"></div> | <img src="https://static.igem.org/mediawiki/2017/9/9d/T--Kent--HP5.png"></div> | ||
</section> | </section> | ||
| Line 609: | Line 620: | ||
<label class="hull-title" for="cb4">Dr. Emma Mead</label> | <label class="hull-title" for="cb4">Dr. Emma Mead</label> | ||
<label class="hull-close" for="acc-close"></label> | <label class="hull-close" for="acc-close"></label> | ||
| − | <div class="hull-content">Through research, we were able to conclude the best possible cells to transfect our constructs into would have to be HEK293 cells. However, without experience in such a field, we were guided to Dr. Mead, who proved to be invaluable throughout the entirety of our project. She confirmed that it would indeed have to be the HEK293 cells and provided us with samples to work with, as well as guiding us through the passaging and transfection itself. | + | <div class="hull-content">Through research, we were able to conclude the best possible cells to transfect our constructs into would have to be HEK293 cells. However, without experience in such a field, we were guided to Dr. Mead, who proved to be invaluable throughout the entirety of our project. She confirmed that it would indeed have to be the HEK293 cells and provided us with samples to work with, as well as guiding us through the passaging and transfection itself.<br> |
<img src="https://static.igem.org/mediawiki/2017/5/5a/T--Kent--HP6.png"></div> | <img src="https://static.igem.org/mediawiki/2017/5/5a/T--Kent--HP6.png"></div> | ||
</section> | </section> | ||
| Line 617: | Line 628: | ||
<label class="hull-title" for="cb5">Dr. Rosalyn Masterton</label> | <label class="hull-title" for="cb5">Dr. Rosalyn Masterton</label> | ||
<label class="hull-close" for="acc-close"></label> | <label class="hull-close" for="acc-close"></label> | ||
| − | <div class="hull-content">We were able to conclude that we would need a vector to clone our construct before we could image it and decided upon pcDNA 3.1 (+) mammalian vector through the help of Dr. Masterton with her expertise in molecular biology. She also advised us who to speak to for the use of mammalian cell lines. | + | <div class="hull-content">We were able to conclude that we would need a vector to clone our construct before we could image it and decided upon pcDNA 3.1 (+) mammalian vector through the help of Dr. Masterton with her expertise in molecular biology. She also advised us who to speak to for the use of mammalian cell lines.<br> |
<img src="https://static.igem.org/mediawiki/2017/b/bf/T--Kent--HP7.png"></div> | <img src="https://static.igem.org/mediawiki/2017/b/bf/T--Kent--HP7.png"></div> | ||
</section> | </section> | ||
Latest revision as of 03:03, 16 December 2017
Integrated HP
Our team has strived to make human practices the solid foundation of our project right from the start. We wanted to ensure we fully understood the implications of any project we chose to pursue while addressing current global problems.
We held a brainstorming session where we bounced ideas off of one another for potential project ideas and had narrowed it down to a top five. We decided we needed to consult with our immediate community to scope out what issues they deemed important that needed immediate addressing. Through different outreach opportunities, we were able to comprehend the controversy surrounding GMOs and genetic engineering in general. This caused us to critically analyze our project ideas before deciding upon ‘LuCAS’: a novel way of mRNA localization using CRISPR - dCas13a.
Why CRISPR-dCas13a (C2C2)?
We were introduced to CRISPR-Cas9 as a tool for targeting cellular mRNA translation through Dr. Peter Ellis, a lecturer in Molecular Biology and Reproduction. However, through research, we discovered that Cas9 is a DNA endonuclease, meaning it recognizes DNA targets and cuts them. It would need to be ‘tricked’ by molecular means. C2C2, however, or Cas13a is an RNA endonuclease, meaning it cuts the RNA rather than the DNA. There are two key differences when comparing Cas13 to CAS9: Firstly, Cas13 recognizes RNA rather than DNA. Secondly, once the target is recognized, it acts promiscuously and starts to ‘chew up’ all of the RNA around it, not only the intended target sequence. 
We wanted to utilize this knowledge and build upon the CRISPR-Cas9 and produce a tool that would just track the mRNA, not cut it. We did not want to overcomplicate our methodology and deemed tagging the mRNA with GFP would be sufficient as we would be able to essentially track the mRNA movement to ensure its localization without damaging its integrity through cutting it.
